A traditional Chinese medicine composition for treating coronary heart disease combined with anxiety and depression and a preparation method thereof

Abstract

The application discloses a traditional Chinese medicine composition for treating coronary heart disease combined with anxiety and depression and a preparation method of the traditional Chinese medicine composition. The composition comprises the following components in parts by weight: American ginseng powder 3-10 parts, panax notoginseng powder 3-6 parts, amber powder 1-2 parts, curcuma zedoaria powder 3-10 parts and hypericum perforatum powder 1-5 parts. The composition can effectively treat coronary heart disease combined with anxiety and depression.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating coronary heart disease combined with anxiety and depression and a preparation method thereof. BACKGROUND

[0002] Acute myocardial infarction (AMI) is the most common and highest prevalence of malignant cardiovascular events, which seriously threatens the life and health of patients. With the gradual improvement of people's living standards and the change of lifestyle, the incidence of angina pectoris of coronary heart disease has also gradually increased. The China Cardiovascular Health and Disease Report 2021 pointed out that cardiovascular disease is still one of the main causes of death in China at present, and an average of 2 out of 5 patients died of cardiovascular disease, and it is estimated that there are about 11.39 million patients with coronary heart disease in China at present. At the same time, for myocardial infarction, the report also pointed out that the mortality rate of myocardial infarction patients has a rising trend year by year.

[0003] Due to the panic caused by repeated attacks of angina pectoris, lack of relevant knowledge, and economic pressure caused by a long course of disease, many patients will have varying degrees of anxiety and depression symptoms. In 1995, Professor Hu Dayi pointed out that in addition to focusing on the heart disease of patients, the mental health of patients should not be ignored, and proposed the "double heart medicine" diagnosis and treatment mode, and the influence of emotions on the condition of patients with coronary heart disease has also gradually been taken seriously. Anxiety and depression are one of the most common and debilitating personal and public health problems in the world, and a study published in the Lancet by Malhi et al. showed that the probability of a person's lifetime is about 15%-18%, and almost one-fifth of people will experience depression in their lifetime. In 2008, the World Health Organization (WHO) also pointed out that by 2030, depression will become the leading global disease burden.

[0004] Current research shows that patients with acute myocardial infarction or ischemic heart disease have a risk of developing anxiety and depression, and depression in patients after myocardial infarction is also associated with increased mortality and morbidity risk, as well as higher readmission rates and future cardiac events.

[0005] Studies have shown that adverse emotions such as anxiety and depression are one of the important independent risk factors for the onset of coronary heart disease. Currently, for the treatment of AMI patients combined with anxiety and depression, Western medicine mainly uses coronary heart disease conventional drugs combined with anti-anxiety and anti-depression drugs. However, due to concerns about the adverse reactions and dependence of psychotropic drugs, many patients have a resistance to such drugs, resulting in poor compliance, irregular medication, and other phenomena, which affect the efficacy of the drugs. Therefore, the efficacy of traditional Chinese medicine for myocardial infarction combined with anxiety and depression needs to be further explored. In view of this, the present application is proposed. SUMMARY

[0006] The present application aims at overcoming the deficiencies of the prior art, and provides a Chinese medicinal composition for treating coronary heart disease combined with anxiety and depression and a preparation method thereof.

[0007] To achieve the above technical purposes, the present application adopts the following technical solutions:

[0008] The present application provides a Chinese medicinal composition for treating coronary heart disease combined with anxiety and depression, which comprises the following components by weight: American ginseng powder 3-10 parts, panax notoginseng powder 3-6 parts, amber powder 1-2 parts, curcuma zedoaria powder 3-10 parts, and hypericum perforatum powder 1-5 parts.

[0009] Optionally, the composition comprises the following components by weight:

[0010] American ginseng powder 3 parts, panax notoginseng powder 3 parts, amber powder 1.5 parts, curcuma zedoaria powder 3 parts, and hypericum perforatum powder 3 parts.

[0011] Optionally, the composition comprises the following components by weight:

[0012] American ginseng powder 6 parts, panax notoginseng powder 4.5 parts, amber powder 1 part, curcuma zedoaria powder 6 parts, and hypericum perforatum powder 1 part.

[0013] Optionally, the composition comprises the following components by weight:

[0014] American ginseng powder 10 parts, panax notoginseng powder 6 parts, amber powder 2 parts, curcuma zedoaria powder 10 parts, and hypericum perforatum powder 5 parts.

[0015] The present application also provides a preparation method of the Chinese medicinal composition for treating coronary heart disease combined with anxiety and depression, which comprises the following steps:

[0016] Preparing medicinal decoction pieces according to the components of the Chinese medicinal composition for treating coronary heart disease combined with anxiety and depression described above;

[0017] Drying the medicinal decoction pieces, and controlling the water content of each dried decoction piece to be less than 6%; then grinding and crushing each dried decoction piece in a micro-powder grinder, and then inputting the ground and crushed decoction pieces into a superfine grinder to form superfine powder; controlling the particle size of the American ginseng powder, panax notoginseng powder and hypericum perforatum powder to be 150-200 meshes, and controlling the particle size of the amber powder and curcuma zedoaria powder to be 80-100 meshes; and preparing edible Chinese medicinal superfine powder according to the proportions of the superfine powder.

[0018] Optionally, the preparation method further comprises the following steps:

[0019] Placing the Chinese medicinal superfine powder into an inner package for infrared disinfection and sterilization, and performing quantitative packaging.

[0020] Optionally, the water content of each dried decoction piece is controlled to be less than 5%.

[0021] The Chinese medicine composition for treating coronary heart disease combined with anxiety and depression and the preparation method provided by the application can improve the inflammatory expression level and the degree of vasodilation of rats with myocardial infarction combined with psychological stress, thereby playing a role in improving the heart function and stress state of the rats. In the composition, Panax quinquefolium is used to replace Panax ginseng as the monarch drug to greatly tonify primordial qi; Panax notoginseng and amber are used as the ministerial drugs to jointly play the roles of activating blood and resolving stasis and calming the mind; Yujin and Hypericum perforatum are used to enhance the functions of soothing the liver and regulating qi, activating blood and resolving depression. The composition is suitable for patients with the main clinical symptoms of chest pain, insomnia, dreaminess, fatigue, shortness of breath, mental depression or restlessness, chest discomfort, dark tongue or blood stasis, and thin or weak pulse. The composition is used for treating coronary heart disease combined with anxiety or depression and is used for treating the syndrome of qi deficiency, blood stasis and liver depression according to TCM differentiation. BRIEF DESCRIPTION OF DRAWINGS

[0022] Figure 1 An ultrasonic image (A, sham operation group; B, sham operation+CUMS group; C, AMI group; D, AMI+CUMS group; E, paroxetine group; F, small Anshen group; G, large Anshen group) of the effect of the Chinese medicine composition for treating coronary heart disease combined with anxiety and depression and other experimental groups on the heart function of rats is provided for the embodiments of the application;

[0023] Figure 2 A result graph of HE staining of the heart tissue of rats (A, sham operation group; B, sham operation+CUMS group; C, AMI group; D, AMI+CUMS group; E, paroxetine group; F, small Anshen group; G, large Anshen group) is provided for the embodiments of the application;

[0024] Figure 3 A result graph of HE staining of the brain tissue of rats (A, sham operation group; B, sham operation+CUMS group; C, AMI group; D, AMI+CUMS group; E, paroxetine group; F, small Anshen group; G, large Anshen group) is provided for the embodiments of the application. DETAILED DESCRIPTION

[0025] In order for those skilled in the art to better understand the scheme of the present application, the technical solutions in the embodiments of the present application will be clearly and completely described in combination with the drawings in the embodiments of the present application. Obviously, the described embodiments are only a part of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without making creative efforts should be within the protection scope of the present application.

[0026] The inventors have found that, as a disease with chest tightness and chest pain as the main clinical manifestations, coronary heart disease belongs to the category of "chest impediment and heart pain" in traditional Chinese medicine. The disease is located in the heart and is of deficiency in the root and excess in the branch. Anxiety and depression, as a group of clinical emotional diseases with low mood, restlessness, chest fullness, and other clinical manifestations, belong to the category of "depression" in traditional Chinese medicine.

[0027] At present, the understanding of the etiology and pathogenesis of coronary heart disease combined with anxiety and depression is different in clinic. The inventors believe that the disease is located in the heart and is closely related to the liver, spleen and kidney. The disease is of deficiency and excess. The deficiency is mainly due to deficiency of qi, blood, yin and yang, and the heart spirit is not nourished. The excess is mainly due to liver depression, qi stagnation, phlegm and fire disturbing the heart, and blood stasis. Depression is mostly a qi disease, and chest impediment is mostly a blood disease. Qi depression and blood stasis, block the heart vessels, and disturb the heart spirit. Therefore, coronary heart disease combined with anxiety and depression is caused by disharmony of qi and blood, and the disease is caused by deficiency and stasis. The pathogenesis is blood stasis, restlessness of heart spirit, disharmony of qi and blood, and deficiency of heart qi (yang).

[0028] In view of this, the embodiment of the present application provides a kind of traditional Chinese medicine composition for treating coronary heart disease combined with anxiety and depression, which is described in detail as follows.

[0029] The traditional Chinese medicine composition for treating coronary heart disease combined with anxiety and depression provided by the embodiment of the present application includes the following components by weight: American ginseng powder 3-10 parts, panax notoginseng powder 3-6 parts, amber powder 1-2 parts, curcuma zedoaria powder 3-10 parts, and hypericum perforatum powder 1-5 parts. Each kind of traditional Chinese medicine decoction piece is selected by a material selection machine and then dried in a drying machine. The water content of each kind of traditional Chinese medicine decoction piece after drying is controlled to be below 5%-6%. Each kind of traditional Chinese medicine decoction piece after drying is input into a micro-powder grinder for grinding and crushing, and then input into a superfine powder grinder to be made into superfine powder. The particle size of American ginseng powder, panax notoginseng powder and hypericum perforatum powder is controlled to be 150-200 meshes, and the particle size of amber powder and curcuma zedoaria powder is controlled to be 80-100 meshes. The superfine powder traditional Chinese medicine is made into edible superfine powder traditional Chinese medicine according to the proportion, 1 g of crude drug per gram, and the superfine powder traditional Chinese medicine is put into an inner package for infrared disinfection and sterilization, and then is quantitatively packaged. The storage is convenient, and the superfine powder traditional Chinese medicine can be eaten at any time and can be taken with boiling water. One bag is taken each time. For water decoction, the above components can be matched according to the ratio of 6:3:1.5:10:3.

[0030] Example 1

[0031] The traditional Chinese medicine composition for treating coronary heart disease combined with anxiety and depression provided by the embodiment of the present application includes the following components: American ginseng powder 3 g, panax notoginseng powder 3 g, amber powder 1.5 g, curcuma zedoaria powder 3 g, and hypericum perforatum powder 3 g. The preparation method is the same as described above, and is not repeated here. The human dose (the amount of decoction piece used per day) is 13.5 g.

[0032] Example 2

[0033] The embodiment is different from the embodiment 1 in that the allocation ratio of each component is different, specifically: American ginseng powder 6g, panax notoginseng powder 4.5g, amber powder 1g, curcuma zedoary powder 6g, hypericum perforatum powder 1g.

[0034] The rest of the preparation method is the same as that in the embodiment 1.

[0035] Embodiment 3

[0036] The embodiment is different from the embodiment 1 in that the allocation ratio of each component is different, specifically: American ginseng powder 6g, panax notoginseng powder 4.5g, amber powder 1g, curcuma zedoary powder 6g, hypericum perforatum powder 1g.

[0037] The rest of the preparation method is the same as that in the embodiment 1.

[0038] The prescription benefits qi and blood, relieves depression and tranquilizes the mind. The main clinical symptoms are chest pain, insomnia, fatigue, shortness of breath, depression or restlessness, and discomfort in the chest and hypochondrium, dark tongue or ecchymosis, and thin or weak pulse. It is used for the treatment of coronary heart disease combined with anxiety or depression, and is used for the treatment of qi deficiency and blood stasis and liver depression syndrome.

[0039] In the following, the effect of the traditional Chinese medicine composition for treating coronary heart disease combined with anxiety and depression provided by the embodiment of the application is introduced through relevant tests. It should be noted that, for the convenience of introduction or description, the "Yiqi Huoxue Anshen Prescription" appearing in the test examples below refers to the traditional Chinese medicine composition for treating coronary heart disease combined with anxiety and depression of the embodiment 1 of the application, and the "Anshen large group", "Anshen small group" and the like all refer to the experimental group of the traditional Chinese medicine composition for treating coronary heart disease combined with anxiety and depression provided by the embodiment 1 of the application.

[0040] Test example: observation on the effect of Yiqi Huoxue Anshen Prescription (American ginseng, panax notoginseng, amber, curcuma zedoary and hypericum perforatum) on the heart function and brain neurotransmitters of acute myocardial infarction (AMI) model rats combined with anxiety and depression.

[0041] 1. Materials and methods

[0042] 1.1 Experimental animals

[0043] Wistar rats, half male and half female, SPF level, provided by Beijing Vantoll Life-Science Experimental Animals Technology Co., Ltd. Barrier level animal room feeding, regular feeding with full value nutrition feed, the rat maintenance feed is provided by Beijing Keao Cooperation Feed Co., Ltd., production qualified certificate: Jing Shi Zhen (2014) 06054. Room temperature (22-25) ℃, humidity 50%-70%, light 12h, dark 12h, adapt to feeding for 1 week before experiment.

[0044] 1.2 Drugs and reagents

[0045] Yiqi Huoxue Anshen Decoction (composed of American ginseng powder, Sanqi powder, amber powder, Yujin powder, and Hypericum perforatum powder, ratio: 3:3:1.5:3:3), provided by the Preparation Room of Xiyuan Hospital of China Academy of Chinese Medical Sciences. Considering that most of the drugs are precious medicinal materials, the preparation adopts the crushing and pressing process. Each kind of traditional Chinese medicine decoction piece is selected by a material selection machine and then dried in a drying machine. The water content of each kind of dried traditional Chinese medicine decoction piece is controlled below 5%-6%. Each kind of dried traditional Chinese medicine decoction piece is then input into a micro-powder grinder for grinding and crushing and into a superfine powder grinder for making superfine powder. The particle size of American ginseng powder, Sanqi powder, and Hypericum perforatum powder is controlled at 150-200 meshes, and the particle size of amber powder and Yujin powder is controlled at 80-100 meshes. The superfine powder of traditional Chinese medicine is made according to the ratio, 1 g of crude drug per gram, and then sterilized by infrared rays in the inner packaging. The traditional Chinese medicine superfine powder is quantitatively packaged. It is convenient to store and can be eaten at any time. It can be taken with boiling water, one bag each time.

[0046] Seroxat (paroxetine hydrochloride tablets containing paroxetine tablets, 20 mg), produced by Tianjin Schering-Plough Pharmaceuticals Co., Ltd., batch number: GMP code H10950043.

[0047] 1.3 Preparation of acute myocardial infarction combined with anxiety and depression model

[0048] Acute myocardial infarction was induced by coronary artery ligation. The long-term survival model after acute myocardial infarction was established by ligation of the left anterior descending coronary artery in vivo as previously established. After abdominal anesthesia (2% pentobarbital solution, 2 mg / kg body weight), the chest was shaved with a small animal hair clipper, and the skin was incised and the subcutaneous tissue and muscle were separated layer by layer. The intercostal space was tonically separated at the heart apex (3-4 intercostal spaces), and the heart was quickly squeezed out. An ophthalmic suture needle was used to thread and ligate the left anterior descending coronary artery 2 mm below the left atrial appendage and the pulmonary artery conus. Then the heart was quickly replaced, the air in the thoracic cavity was squeezed out, and the thoracic cavity was closed. The above operations were performed under strict sterile conditions. The formation of AMI was shown by the ST segment elevation in the standard limb lead II electrocardiogram. The sham operation group was the same as the AMI model animals except that the coronary artery was not ligated. Postoperative penicillin 40,000 IU was given.

[0049] The anxiety and depression model uses the chronic unpredictable stress model. Considering the laboratory environment and the limitations of AMI rats, the stressor of CUMS model is improved. After the AMI rat model is successfully established for 24 hours, chronic mild CUMS is used. For 4 weeks, the rats are given mild unpredictable stimulation every day. The stimulation method is as follows: water deprivation for 24 hours; food deprivation for 24 hours; shaking the cage for 15 minutes (to the extent that the rat cannot stand stably); tail clamping for 5 minutes; ice water (4°C) swimming for 5 minutes; 24 hours of day-night reversal, the paper box is taken out at 6 am on the day to cause a dark environment, and the cage is placed in a light environment at 6 pm on the day, with 12 hours of light, and the paper box is taken back at 6 am on the second day; humid environment for 24 hours; pepper is sprinkled into the cage for 24 hours of odor stimulation; sleep deprivation for 24 hours. From 9:00 to 17:00 every day, one kind of stimulation is randomly selected to make the rats unable to predict the occurrence of stimulation. The success of modeling is checked by sugar water preference test and open field test, and the experimental period is 28 days.

[0050] 1.4 Animal grouping

[0051] After 24 hours of modeling, the surviving rats will enter the experimental group. A total of 98 rats were modeled, 62 survived, and the survival rate was 63.26%. After successful modeling, the rats were divided into the following groups according to the random number table method: sham operation group, sham operation + CUMS group, acute myocardial infarction group (AMI group), AMI + CUMS group, positive control drug (hydrochloric acid paroxetine tablet) group (western medicine group, 1.8 mg hydrochloric acid paroxetine tablet / kg body weight), small dose of Yiqi Huoxue Anshen Decoction group (small Anshen group, 1.20 g crude drug / kg body weight), large dose of Yiqi Huoxue Anshen Decoction group (large Anshen group, 2.40 g crude drug / kg body weight), 10 rats in each group. From the second day after the operation, the rats in the sham operation + CUMS group, AMI + CUMS group, western medicine group, small Anshen group, and large Anshen group were given chronic mild unpredictable stimulation. At the same time, the rats in each group were given equal volume of solution by gavage for 28 days. Among them, the sham operation group, sham operation + CUMS group, AMI group, and AMI + CUMS group were given equal volume of pure water by gavage. After the last stress and gavage, the rats were subjected to animal behavior detection, and heart ultrasound examination was performed after abdominal anesthesia.

[0052] Subsequently, the rats were fixed in a supine position on a rat plate, and abdominal aortic blood was taken, and serum was obtained by centrifugation for standby. The rat heart and brain were taken, and 5 (or 4) rats were randomly placed in 10% neutral formaldehyde solution for pathological section observation. Another 5 rats were placed in a-80°C refrigerator for storage, and Western-blot detection was performed to observe the expression of autophagy-related proteins LC3B-II and Beclin-1 and the expression of key proteins in the PI3K / Akt / mTOR pathway. During the experiment, the treatment of animals conforms to the animal ethics requirements stipulated in the “Regulations for the Administration of Laboratory Animals” of the National Science and Technology Commission and the “Beijing Laboratory Animal Welfare Ethics Review Guidelines” of Beijing, and the animal experiment is approved by the Ethics Committee of Xiyuan Hospital of China Academy of Chinese Medical Sciences (No.: 2021XLC039-2).

[0053] 1.5 Rat cardiac ultrasonic detection method

[0054] On the day of gavage, the rats were anesthetized and subjected to 2D M-mode echocardiography. The rats were fixed in a supine position on a surgical plate for cardiac ultrasound examination. 7-15 MHz Z A linear array probe (model: CL15-7, produced by Philips (China) Investment Co., Ltd.) was placed on the left chest, and after obtaining satisfactory parasternal short-axis left ventricular two-dimensional images, an ultrasonic diagnostic instrument (model: HDI5000, produced by Philips (China) Investment Co., Ltd.) was used to obtain M-mode echocardiogram at the papillary muscle level by making the M-mode sampling line perpendicular to the interventricular septum and the atrium and left ventricle.

[0055] The cardiac ultrasound functional indicators of the same cardiac cycle include ejection fraction (EF), cardiac output (CO), left ventricular short-axis fractional shortening (FS), and stroke volume (SV), left ventricular anterior wall (LVAW) and posterior wall (LVPW) thickness. The original data of each group were measured for 3 consecutive cardiac cycles, and the ultrasound examination was performed by two experienced doctors who did not know the grouping of the rats.

[0056] 1.6 Preparation of rat myocardial tissue and brain tissue pathology

[0057] After cardiac ultrasound detection, the rats in each group were sacrificed, and the rat brain tissue and infarct tissue were removed and fixed with polyformaldehyde. After 24 hours, the fixed tissue was paraffin-embedded, sectioned, and the thickness of the section was 4 μm. After deparaffinization, HE staining was performed and observed.

[0058] 1.7 Detection of rat brain neurotransmitters

[0059] The removed rat brain tissue was separated into cortex and hippocampus. The rat hippocampus tissue was mixed with physiological saline in ice bath at 1:3, homogenized, centrifuged, and the supernatant was taken. The protein was quantitatively detected by BCA (bicinchoninic acid, BCA) compound. The contents of norepinephrine (NOR), dopamine (DA) and serotonin (5-HT) were detected by ELISA method, and the neurotransmitter concentration was converted.

[0060] 1.8 Detection of rat serum myocardial enzymes

[0061] CK-MB was detected by (colorimetric) immunosuppression method, and cTnT was detected by ELISA immunocompetitive method. The detection operation was strictly performed according to the instructions of the kit.

[0062] 1.9 Statistical processing

[0063] SPSS 13.0 software was used for processing. The experimental data was represented by x±s, and the normal distribution analysis was performed. The statistical data was analyzed by one-way ANOVA, and the LSD was used for pairwise comparison when the variance was homogeneous. When the variance was not homogeneous, Dunnett T3 was used for pairwise comparison, and P<0.05 was considered to have statistical significance.

[0064] 2. Results

[0065] 2.1 Effect of Yiqi Huoxue Anshen Decoction on the behavior of AMI+CUMS model rats

[0066] Compared with the sham operation group, the total distance, central area distance, central area latency and sugar water preference of the sham operation+CUMS group rats decreased (P<0.05, P<0.01); the total distance and central area distance of the AMI group rats decreased (P<0.05, P<0.01), and the latency and sugar water preference showed no obvious change; compared with the AMI group, the total distance, central area distance, central area latency and sugar water preference of the AMI+CUMS group rats decreased (P<0.05, P<0.01); compared with the AMI+CUMS group rats, the total distance, central area distance, central area latency and sugar water preference of the western medicine group rats increased (P<0.05, P<0.01); the total distance of the Anshen small group rats increased (P<0.05), and the central area distance, central area latency and sugar water preference showed no obvious improvement; the total distance and sugar water preference of the Anshen large group rats increased (P<0.05, P<0.01), and the central area distance and central area latency showed no obvious change. The results are shown in Table 1.

[0067] Table 1. Effect of Yiqi Huoxue Anshen Decoction on the behavior of rats

[0068]

[0069] Note: compared with the sham operation group, ▲ P<0.05, ▲▲ P<0.01; compared with the AMI group, # P<0.05, ## P<0.01; compared with the AMI+CUMS group, * P<0.05, ** P<0.01

[0070] 2.2 Effect of Yiqi Huoxue Anshen Decoction on cardiac function of AMI+CUMS model rats

[0071] Compared with the sham operation group, the ejection fraction, cardiac output, left ventricular fractional shortening and stroke volume of the sham operation+CUMS group were not significantly changed; the ejection fraction, cardiac output, left ventricular fractional shortening and stroke volume of the AMI group were decreased (P<0.01). Compared with the AMI group, the ejection fraction and cardiac output of the AMI+CUMS group were decreased (P<0.05), and the left ventricular fractional shortening and stroke volume were not significantly changed. Compared with the AMI+CUMS group, the ejection fraction and stroke volume of the paroxetine group were increased (P<0.01, P<0.05), and the left ventricular fractional shortening and cardiac output were not significantly changed; the ejection fraction of the small Anshen group was increased (P<0.05), and the cardiac output, left ventricular fractional shortening and stroke volume were not significantly changed; the ejection fraction, cardiac output, left ventricular fractional shortening and stroke volume of the large Anshen group were increased (P<0.01, P<0.05). The results are shown in Table 2 and Figure 1 .

[0072] Table 2. Effect of Yiqi Huoxue Anshen Decoction on cardiac ultrasound function of rats

[0073]

[0074] Note: compared with the sham operation group, ▲ P<0.05, ▲▲ P<0.01; compared with the AMI group, # P<0.05, ## P<0.01; compared with the AMI+CUMS group, * P<0.05, ** P<0.01

[0075] 2.3 Effect of Yiqi Huoxue Anshen Decoction on myocardial histopathology of AMI+CUMS model rats

[0076] Under light microscope, the myocardial tissue of ischemic area in rats was observed. The myocardial cell tissue of rats in sham operation group and sham operation + CUMS group was arranged in order, with complete contour and uniform staining, and no obvious inflammatory cell infiltration, edema, degeneration and necrosis were observed. The myocardial tissue of rats in AMI group and AMI + CUMS group showed obvious texture disorder, and the number of myocardial cells was reduced, and local flaky cell necrosis, a large number of myofilament dissolution and inflammatory cell infiltration were observed. Compared with AMI group, the infarct area of myocardial tissue in AMI + CUMS group was larger, and the interstitial edema, karyopyknosis and inflammatory infiltration were more serious. Compared with AMI + CUMS group, the myocardial injury degree and range of ischemic area in rats of each drug intervention group were obviously improved, the number of myocardial cells was increased, the pathological structure was partially relieved, and the inflammatory infiltration was reduced. The results are shown in Figure 2 .

[0077] 2.4 Effect of Yiqi Huoxue Anshen Decoction on brain tissue pathology of AMI + CUSM model rats

[0078] The structure of hippocampal region of rats in sham operation group was complete, the cells were arranged in order, the number was large, the density was large, the hierarchy was clear, and the nuclear morphology of nerve cells was normal. The number of hippocampal cells of rats in AMI group was reduced, the morphology was normal, and the density was reduced. The number of hippocampal cells of rats in sham operation + CUMS group and AMI + CUMS group was reduced, the density was reduced, the cell nucleus was damaged, the cell body was pyknosis, and the cytoplasm was dissolved. Compared with AMI + CUMS group, the number of nerve cells in hippocampal region of rats in each drug intervention group was relatively increased, arranged closely, and the cytoplasm was stained uniformly. The results are shown in Figure 3 .

[0079] 2.5 Effect of Yiqi Huoxue Anshen Decoction on serum CK-MB and cTnT of AMI + CUSM model rats

[0080] Compared with sham operation group, the serum cTnT and CK-MB levels of rats in sham operation + CUMS group were not obviously changed; the serum cTnT level of rats in AMI group was increased (P<0.01), and the CK-MB level was not obviously changed. Compared with AMI group, the serum CK-MB level of rats in AMI + CUMS group was increased (P<0.05), and the cTnT level was not obviously changed. Compared with AMI + CUMS group, the serum cTnT level of rats in paroxetine group was decreased (P<0.01), and the CK-MB level was not obviously changed; the serum CK-MB and cTnT levels of rats in small and large Anshen groups were decreased (P<0.01). The results are shown in Table 3.

[0081] Table 3. Comparison of CK-MB and cTnT levels in each group

[0082]

[0083] Note: Compared with the sham operation group, ▲ P<0.05, ▲▲ P<0.01; compared with the AMI group, # P<0.05, ## P<0.01; compared with the

[0084] AMI+CUMS group, * P<0.05, ** P<0.01

[0085] 2.6 Effect of Yiqi Huoxue Anshen Decoction on neurotransmitters in brain tissue of AMI+CUMS model rats

[0086] Compared with the sham operation group, NOR, 5-HT and DA levels in brain tissue of the sham operation+CUMS group were decreased (P<0.05, P<0.01), and ROS level showed no obvious change; ROS level in brain tissue of the AMI group was increased (P<0.01), and NOR, 5-HT and DA levels showed no obvious change. Compared with the AMI group, NOR, 5-HT and DA levels in brain tissue of the AMI+CUMS group were decreased (P<0.05, P<0.01), and ROS level showed no obvious change. Compared with the AMI+CUMS group, NOR and 5-HT levels in brain tissue of the paroxetine group were increased, ROS level was decreased (P<0.05, P<0.01), and DA level showed no obvious change; NOR and 5-HT levels in brain tissue of the small Anshen group were increased, ROS level was decreased (P<0.05, P<0.01), and DA level showed no obvious change; NOR, 5-HT and DA levels in brain tissue of the large Anshen group were increased, and ROS level was decreased (P<0.05, P<0.01). The results are shown in Table 4.

[0087] Table 4. Comparison of NOR, 5-HT, DA and ROS levels in brain hippocampal tissue of each group

[0088]

[0089] Note: Compared with the sham operation group, ▲ P<0.05, ▲▲ P<0.01; compared with the AMI group, # P<0.05, ## P<0.01; compared with the AMI+CUMS group, * P<0.05, ** P<0.0

[0090] In summary, the TCM believes that coronary heart disease combined with anxiety and depression should belong to the category of 'chest pain' and 'depression'. Chest pain and depression are interrelated and influence each other. The core of the disease is deficiency in origin and excess in superficiality. The disease is located in the heart and its nature is deficiency in origin and excess in superficiality. Based on the theory of qi and blood, we believe that depression is mostly qi disease and chest pain is mostly blood disease. Qi depression and blood stasis, block the heart vessels, disturb the heart spirit, so coronary heart disease combined with anxiety and depression is caused by qi and blood disharmony. Deficiency leads to stasis, and stasis leads to depression. The main symptoms of the disease are blood stasis and heart spirit disturbance, and the root cause is qi and blood disharmony and heart qi deficiency.

[0091] Yiqi Huoxue Anshen Decoction is based on the 'Sanqi Shensu San' used by Professor Yue Meizhong, a famous TCM doctor, to treat coronary heart disease and angina pectoris. In this formula, American ginseng replaces ginseng as the monarch, which greatly supplements the primordial qi. Sanqi and shensu serve as the ministers, which together activate blood and resolve stasis, and calm the mind. Yujin and Huan-ye Jin-si-tao are added to enhance the functions of soothing the liver, regulating qi, activating blood and resolving depression. It is suitable for patients with chest pain, insomnia, fatigue, shortness of breath, depression or restlessness, and discomfort in the chest and hypochondriac region. It is mainly used to treat coronary heart disease combined with anxiety or depression, and the TCM syndrome is qi deficiency, blood stasis and liver depression.

[0092] After acute myocardial infarction, the blood flow of coronary artery decreases, the oxygen supply of myocardium is insufficient, and the myocardial cells and myocardial fibroblasts change, inducing ventricular remodeling (VR), which leads to decreased left ventricular compliance and decreased ejection fraction, and ultimately leads to adverse events such as chronic heart failure. LVEF is the preferred index for evaluating the left ventricular overall systolic function of acute coronary syndrome and ischemic cardiomyopathy. The experimental results show that compared with the sham operation group, the CO, FS and SV of the model group rats decreased to varying degrees, the diastolic and systolic function of the heart decreased, the ejection function decreased, and the EF value decreased. Both large and small doses of paroxetine and Yiqi Huoxue Anshen Decoction can improve the ejection fraction of acute myocardial infarction combined with anxiety and depression model rats to varying degrees, and improve the cardiac function of rats. In the open field test, the total distance of the Anshen group increased, the center area distance and the center area latency did not change significantly, and the sugar water preference increased. The NOR, 5-HT and DA levels of brain tissue increased, and the ROS level decreased. The ejection fraction, cardiac output, left ventricular short axis shortening rate, per-beat cardiac output, left ventricular mass, and left ventricular posterior wall thickness of the heart increased, and the left ventricular anterior wall thickness decreased.

[0093] In summary, Yiqi Huoxue Anshen Decoction can improve the systolic function of the heart and the level of neurotransmitters in rats with myocardial infarction combined with psychological stress, improve cognitive function, reduce the level of active oxygen and inflammation, and reduce myocardial ischemic injury, thereby improving the heart function and anxiety and depression state.

Claims

1. A traditional Chinese medicine composition for treating coronary heart disease combined with anxiety and depression, characterized in that, By weight parts consisting of: American ginseng powder 3 parts, sanchi powder 3 parts, amber powder 1.5 parts, yujin powder 3 parts, hypericum perforatum powder 3 parts.

2. A preparation method of a traditional Chinese medicine composition for treating coronary heart disease combined with anxiety and depression, characterized in that, Comprise: The component preparation of the traditional Chinese medicine composition for treating coronary heart disease combined with anxiety and depression according to claim 1 prepares medicine decoction pieces; The medicine decoction pieces are dried, and the water content of each decoction piece after drying is controlled to be below 6%; Each decoction piece after drying is respectively input into a micro-powder grinder for grinding and crushing, and then respectively input into a superfine powder grinder to form superfine powder, the particle size of American ginseng powder, sanchi powder and hypericum perforatum powder is controlled to be 150-200 meshes, the particle size of amber powder and yujin powder is controlled to be 80-100 meshes, and the superfine powder is made into edible traditional Chinese medicine superfine powder according to the proportion.

3. The production method according to claim 2, characterized by, The preparation method further comprises: The traditional Chinese medicine superfine powder is placed into an inner package for infrared disinfection and sterilization, and is quantitatively packaged.

4. The production method according to claim 2, characterized by, The water content of each decoction piece after drying is controlled to be below 5%.

Images